Molecular Therapy with Recombinant p53 Adenovirus in an Androgen-Independent, Metastatic Human Prostate Cancer Model

Song-Chu Ko(The University of Texas MD Anderson Cancer Center), Leland W.K. Chung(VA Palo Alto Health Care System), Akinobu Gotoh(Nissin Kogyo (Japan)), Weiwei Zhang(Academy of Medical Sciences), Haiyen E. Zhau(Cedars-Sinai Medical Center), Chinghai Kao(University of Virginia), Dennis A. Johnston, George N. Thalmann(University Hospital of Bern)

Human Gene Therapy

September 10, 1996

10.1089/hum.1996.7.14-1683

Cited by 125

Related Papers

European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines

|European Urology|2020|2.2k

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

|The Lancet|2015|2k

Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy

|European Urology|2017|798

Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer.

|PubMed|1994|739

European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines

|European Urology|2023|656